Abby Hardy, Author at BioTuesdays

Developments

Hepion Pharma CRV431 shows efficacy in kidney fibrosis

Hepion Pharmaceuticals (NASDAQ:HEPA) CRV431 demonstrated antifibrotic activity in an experimental model of renal fibrosis. The study, which was conducted by SMC Laboratories in Tokyo, Japan, evaluated CRV431 in the...

June 22, 2020

Executive Moves

Chimerix appoints Allen Melemed as CMO

Allen Melemed Chimerix (NASDAQ:CMRX) appointed Dr. Allen Melemed as its CMO. Dr. Melemed was most recently a distinguished medical fellow and senior director of North American regulatory affairs oncology at Eli Lilly...

June 22, 2020

Developments

Ziopharm completes enrollment of Phase 2 glioblastoma trial

Ziopharm Oncology (NASDAQ:ZIOP) completed enrollment of 36 subjects in its Phase 2 trial evaluating controlled IL-12, in combination with PD-1 inhibitor cemiplimab, for the treatment of recurrent or progressive...

June 22, 2020

Developments

uniQure doses first patients in Phase 1/2 Huntington’s disease gene therapy trial

uniQure (NASDAQ:QURE) dosed the first two patients in its Phase 1/2 trial evaluating AMT-130 for the treatment of Huntington’s disease (HD). HD is an inherited neurodegenerative disorder where production and aggregation...

June 19, 2020

Developments

Ovid Therapeutics OV101 granted FDA rare pediatric disease designation

Ovid Therapeutics’ (NASDAQ:OVID) OV101 received FDA rare pediatric disease designation for the treatment of Angelman syndrome. Angelman syndrome is a rare genetic disorder that affects the brain’s ability to correctly...

June 19, 2020

Developments

Kane Biotech DispersinB program receives $2.7-million U.S. Department of Defense award

Kane Biotech (TSX-V:KNE; OTCQB:KNIBF) received the U.S. DoD’s Medical Technology Enterprise Consortium (MTEC) Research Project Award for DispersinB. The non-dilutive $2.7-million award will fund continued clinical...

June 18, 2020

Developments

Xeris Pharma posts positive topline data from Phase 2 T1D study

Xeris Pharmaceuticals (NASDAQ:XERS) reported positive topline results from its Phase 2 study of XP-3924, a pramlintide-insulin co-formulation, in adults with Type 1 diabetes (T1D). The trial enrolled 18 adults with T1D...

June 18, 2020

Developments

Aptinyx completes enrollment in Phase 2 PTSD trial

Aptinyx (NASDAQ:APTX) completed enrollment for its Phase 2 study of NYX-783 for the treatment of post-traumatic stress disorder (PTSD). The 160 enrolled patients were randomized to receive either placebo, 10 mg of NYX...

June 18, 2020

Developments

InflaRx reports topline results from Phase 2/3 COVID-19 trial

InflaRx (NASDAQ:IFRX) reported encouraging topline results from the first 30 COVID-19 patients treated with IFX-1 in a Phase 2/3 trial. IFX-1 is a monoclonal anti-human complement factor C5a antibody designed to...

June 17, 2020

Executive Moves

NeuroOne appoints neural engineering expert, Camilo Andres Diaz-Botia, as director of electrode development

Camilo Andres Diaz-Botia NeuroOne Medical Technologies (OTCQB:NMTC) appointed neural engineer, Camilo Andres Diaz-Botia, as director of electrode development. Dr. Diaz-Botia previously led the microfabrication process...

June 17, 2020

Author - Abby Hardy

Hepion Pharma CRV431 shows efficacy in kidney fibrosis

Chimerix appoints Allen Melemed as CMO

Ziopharm completes enrollment of Phase 2 glioblastoma trial

uniQure doses first patients in Phase 1/2 Huntington’s disease gene therapy trial

Ovid Therapeutics OV101 granted FDA rare pediatric disease designation

Kane Biotech DispersinB program receives $2.7-million U.S. Department of Defense award

Xeris Pharma posts positive topline data from Phase 2 T1D study

Aptinyx completes enrollment in Phase 2 PTSD trial

InflaRx reports topline results from Phase 2/3 COVID-19 trial

NeuroOne appoints neural engineering expert, Camilo Andres Diaz-Botia, as director of electrode development

General

More